Trastuzumab Mediated T-Cell Response against HER-2/Neu Overexpressing Esophageal Adenocarcinoma Depends on Intact Antigen Processing Machinery
Francesca Milano, Mirta Guarriera, Agnieszka M. Rygiel et al. · 2010
Read Trastuzumab Mediated T-Cell Response against HER-2/Neu Overexpressing Esophageal Adenocarcinoma Depends on Intact Antigen Processing Machinery by Francesca Milano, Mirta Guarriera, Agnieszka M. Rygiel et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0012424.txt.
Description
Francesca Milano, Mirta Guarriera, Agnieszka Rygiel and colleagues studied the cancer drug trastuzumab in esophageal tumors, in a 2010 PLOS ONE paper. This cancer is aggressive and often carries extra copies of the HER-2 gene, the drug's target. Trastuzumab is an antibody best known from breast cancer care, and it can also rally T cells against tumor cells.
The team found that the T cell attack only worked when the tumor's antigen processing machinery was intact. Tumors that break that machinery can dodge the immune part of the drug. Testing the machinery in patients could help predict who benefits from trastuzumab beyond simple HER-2 counts.
Catalog record
| CREATOR | Francesca Milano, Mirta Guarriera, Agnieszka M. Rygiel et al. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0012424